Literature DB >> 16378496

Drugs to treat inflammation: a historical introduction.

Michael W Whitehouse1.   

Abstract

Drugs to treat inflammation are discussed under the following headings: (1) random discoveries covering copper, salicylates, heterocyclic diones, ACTH, adrenal steroids and disease-modifying agents (DMARDs); these include Au(I)-thiolates, chloroquine, and hydroxychloroquine, minocycline, cyclosporin, salazopyrine, D-penicillamine and methotrexate; (2) programmed NSAID developments covering salicylates and fenamates, arylalkanoates, diones, non-acidic NSAIDs, clozic, lobenzarit and coxibs; (3) synthetic glucocorticosteroids; and (4) 'Biologicals' for neutralising pro-inflammatory cytokines. Clinical problems are highlighted, particularly unacceptable side-effects affecting the GI tract, skin, liver, etc. that caused many drugs to be withdrawn. Drug combinations may overcome some of these problems. The bibliography has selected reviews and monographs covering 50 years of publications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16378496     DOI: 10.2174/092986705774462879

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  10 in total

1.  Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease.

Authors:  K B Baker; N J Spurrier; A S Watkins; J R Smith; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2006-08-16       Impact factor: 4.638

2.  [4 + 2] cycloadditions of N-alkenyl iminium ions: structurally complex heterocycles from a three-component Diels-Alder reaction sequence.

Authors:  Nihar Sarkar; Abhisek Banerjee; Scott G Nelson
Journal:  J Am Chem Soc       Date:  2008-06-25       Impact factor: 15.419

3.  A history of the term "DMARD".

Authors:  Jonas Kure Buer
Journal:  Inflammopharmacology       Date:  2015-05-23       Impact factor: 4.473

Review 4.  To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology.

Authors:  Jonas Kure Buer
Journal:  Inflammopharmacology       Date:  2017-02-13       Impact factor: 4.473

5.  Quasi-Isostructural Co(II) and Ni(II) Complexes with Mefenamato Ligand: Synthesis, Characterization, and Biological Activity.

Authors:  Michał Gacki; Karolina Kafarska; Anna Pietrzak; Izabela Korona-Głowniak; Wojciech M Wolf
Journal:  Molecules       Date:  2020-07-07       Impact factor: 4.411

6.  Regioselective synthesis of heterocyclic N-sulfonyl amidines from heteroaromatic thioamides and sulfonyl azides.

Authors:  Vladimir Ilkin; Vera Berseneva; Tetyana Beryozkina; Tatiana Glukhareva; Lidia Dianova; Wim Dehaen; Eugenia Seliverstova; Vasiliy Bakulev
Journal:  Beilstein J Org Chem       Date:  2020-12-01       Impact factor: 2.883

7.  BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells.

Authors:  Jin-Zhong Zhang; Megan E Cavet; Karl R VanderMeid; Mercedes Salvador-Silva; Francisco J López; Keith W Ward
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

8.  Methotrexate and cyclosporine treatments modify the activities of dipeptidyl peptidase IV and prolyl oligopeptidase in murine macrophages.

Authors:  R A Olivo; N G Nascimento; C F P Teixeira; P F Silveira
Journal:  Clin Dev Immunol       Date:  2008

9.  Design, synthesis, antinociceptive and anti-inflammatory activities of novel piroxicam analogues.

Authors:  Amanda Silva de Miranda; Walfrido Bispo Júnior; Yolanda Karla Cupertino da Silva; Magna Suzana Alexandre-Moreira; Rosane de Paula Castro; José Ricardo Sabino; Luciano Morais Lião; Lídia Moreira Lima; Eliezer J Barreiro
Journal:  Molecules       Date:  2012-11-28       Impact factor: 4.411

Review 10.  The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.

Authors:  Richard Cunningham; Carsten Gram Hansen
Journal:  Clin Sci (Lond)       Date:  2022-02-11       Impact factor: 6.124

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.